Assessment of cisplatin-induced kidney injury using an integrated rodent platform.

Chen Y, Brott D, Luo W, Gangl E, Kamendi H, Barthlow H, Lengel D, Fikes J, Kinter L, Valentin JP, Bialecki R.
Journal   Toxicol Appl Pharmacol
Species  
Analytes Measured   Albumin , Clusterin , GSTYb1 , HAVCR1 KIM-1 , Osteopontin , RPA-1
Matrix Tested   Urine
Year   2013
Volume   268
Page Numbers   352-361
Application   Toxicology
Abstract
Current diagnosis of drug-induced kidney injury (DIKI) primarily relies on detection of elevated plasma creatinine (Cr) or blood urea nitrogen (BUN) levels; however, both are indices of overall kidney function and changes are delayed with respect to onset of nephron injury. Our aim was to investigate whether early changes in new urinary DIKI biomarkers predict plasma Cr, BUN, renal hemodynamic and kidney morphological changes associated with kidney injury following a single dose of cisplatin (CDDP) using an integrated platform in rodent. Conscious surgically prepared male Han Wistar rats were given a single intraperitoneal dose of CDDP (15mg/kg). Glomerular filtration rate (GFR), effective renal plasma flow (ERPF), urinalysis, DIKI biomarkers, CDDP pharmacokinetics, blood pressures, heart rate, body temperature and electroencephalogram (EEG) were measured in the same vehicle- or CDDP-treated animals over 72h. Plasma chemistry (including Cr and BUN) and renal tissues were examined at study termination. Cisplatin caused progressive reductions of GFR, ERPF, heart rate and body temperature from day 1 (0-24h). DIKI biomarkers including alpha-glutathione S-transferase (α-GST) significantly increased as early as 6h post-dose, which preceded significant declines of GFR and ERPF (24h), increased plasma Cr and BUN (72h), and associated with renal acute tubular necrosis at 72h post-dose. The present study adds to the current understanding of CDDP action by demonstrating that early increases in urinary excretion of α-GST predict DIKI risk following acute exposure to CDDP in rats, before changes in traditional DIKI markers are evident.

View Publications

Related Products

R-PLEX Mouse HAVCR1/KIM-1 Assay
HAVCR1/KIM-1 | Mouse
Singleplex
R-PLEX Mouse HAVCR1/KIM-1 Antibody Set
HAVCR1/KIM-1 | Mouse
U-PLEX Human Clusterin 384-Well Assay
Clusterin | Human
Singleplex
U-PLEX Custom Biomarker Group 3 (human) 384-well Assays
Human
Multiplex
U-PLEX Custom Biomarker Group 3 (human) Assays
Human
Multiplex
U-PLEX Human Clusterin Antibody Set
Clusterin | Human
U-PLEX Human Clusterin Assay
Clusterin | Human
Singleplex
U-PLEX Metabolic Combo 2 (human)
Adiponectin, ApoA1, ApoC3, Clusterin, CRP, DPPIV, NGAL/LCN2, RBP4, SHBG, sTfR-1 | Human
Multiplex
U-PLEX Kidney Injury Combo 1 (human)
A2M, Clusterin, Cystatin C, NGAL/LCN2, RBP4, Serpin A1 | Human
Multiplex
R-PLEX Rat Albumin Antibody Set
Albumin | Rat
R-PLEX Human HAVCR1/KIM-1 Assay
HAVCR1/KIM-1 | Human
Singleplex
R-PLEX Human Albumin Assay
Albumin | Human
Singleplex
R-PLEX Human Osteopontin Assay
Osteopontin | Human
Singleplex
R-PLEX Mouse Clusterin Assay
Clusterin | Mouse
Singleplex
R-PLEX Rat HAVCR1/KIM-1 Assay
HAVCR1/KIM-1 | Rat
Singleplex
R-PLEX Rat Albumin Assay
Albumin | Rat
Singleplex
R-PLEX Rat Osteopontin Assay
Osteopontin | Rat
Singleplex
R-PLEX Mouse Clusterin Antibody Set
Clusterin | Mouse
R-PLEX Human Albumin Antibody Set
Albumin | Human
R-PLEX Human HAVCR1/KIM-1 Antibody Set
HAVCR1/KIM-1 | Human
R-PLEX Rat HAVCR1/KIM-1 Antibody Set
HAVCR1/KIM-1 | Rat
R-PLEX Rat Osteopontin Antibody Set
Osteopontin | Rat
R-PLEX Human Osteopontin Antibody Set
Osteopontin | Human
Rat Clusterin Kit
Clusterin | Rat
Singleplex
Kidney Injury Panel 3 Human Kit
Calbindin, Clusterin, HAVCR1/KIM-1, Osteoactivin, TFF3, VEGF-A | Human
Multiplex
Kidney Injury Panel 1 Rat Kit
Albumin, HAVCR1/KIM-1, NGAL/LCN2, Osteopontin | Rat
Multiplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters